Currently, there are 183.21M common shares owned by the public and among those 151.89M shares have been available to trade.
Insiders at the company have transacted a total of 153 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 65 of these insider trades were purchases, accounting for 1,719,960 shares. Insider sales of the common stock occurred on 88 occasions, with total insider shares sold totaling 1,767,641 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 10.24, down -10.47%. The company’s stock has a 5-day price change of 3.32% and 79.40% over the past three months. RXRX shares are trading -0.66% year to date (YTD), with the 12-month market performance up to 19.60% higher. It has a 12-month low price of $4.54 and touched a high of $16.75 over the same period. RXRX has an average intraday trading volume of 1.02 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.83%, 0.36%, and 14.47% respectively.
Institutional ownership of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares accounts for 72.13% of the company’s 183.21M shares outstanding.
It has a market capitalization of $2.11B and a beta (3y monthly) value of 0.67. The earnings-per-share (ttm) stands at -$1.47. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.25% over the week and 7.65% over the month.
Analysts forecast that Recursion Pharmaceuticals Inc (RXRX) will achieve an EPS of $Recursion Pharmaceuticals, Inc. for the current quarter, $9.79 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Xerox Holdings Corporation while analysts give the company a high EPS estimate of $Royalty Pharma plc. Comparatively, EPS for the current quarter was $Regal Rexnord Corporation a year ago. Earnings per share for the fiscal year are expected to decrease by -21.23%, and -11.98% over the next financial year.
Looking at the support for the RXRX, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on May 22, 2023, with the firm’s price target at $8.
